vs
Side-by-side financial comparison of Bio-Techne (TECH) and UNIVERSAL INSURANCE HOLDINGS, INC. (UVE). Click either name above to swap in a different company.
UNIVERSAL INSURANCE HOLDINGS, INC. is the larger business by last-quarter revenue ($393.6M vs $295.9M, roughly 1.3× Bio-Techne). UNIVERSAL INSURANCE HOLDINGS, INC. runs the higher net margin — 13.8% vs 12.8%, a 0.9% gap on every dollar of revenue. On growth, UNIVERSAL INSURANCE HOLDINGS, INC. posted the faster year-over-year revenue change (-0.3% vs -6.4%). Over the past eight quarters, Bio-Techne's revenue compounded faster (4.2% CAGR vs 1.7%).
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
New York Life Insurance Company (NYLIC), most commonly known as New York Life, is the second-largest life insurance company and the largest mutual life insurance company in the United States, and is ranked #69 on the 2025 Fortune 500 list of the largest U.S. corporations by total revenue. In 2025, NYLIC achieved the best possible ratings by the four independent rating companies. Other New York Life affiliates provide an array of securities products and services, as well as institutional and r...
TECH vs UVE — Head-to-Head
Income Statement — Q2 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $295.9M | $393.6M |
| Net Profit | $38.0M | $54.3M |
| Gross Margin | 64.6% | — |
| Operating Margin | 18.4% | — |
| Net Margin | 12.8% | 13.8% |
| Revenue YoY | -6.4% | -0.3% |
| Net Profit YoY | 68.3% | 31.0% |
| EPS (diluted) | $0.24 | $1.88 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $393.6M | ||
| Q4 25 | $295.9M | $407.9M | ||
| Q3 25 | — | $401.0M | ||
| Q2 25 | $317.0M | $400.1M | ||
| Q1 25 | $316.2M | $394.9M | ||
| Q4 24 | $297.0M | $384.8M | ||
| Q3 24 | $289.5M | $387.6M | ||
| Q2 24 | $306.1M | $380.2M |
| Q1 26 | — | $54.3M | ||
| Q4 25 | $38.0M | $66.6M | ||
| Q3 25 | — | $39.8M | ||
| Q2 25 | $-17.7M | $35.1M | ||
| Q1 25 | $22.6M | $41.4M | ||
| Q4 24 | $34.9M | $6.0M | ||
| Q3 24 | $33.6M | $-16.2M | ||
| Q2 24 | $40.6M | $35.4M |
| Q1 26 | — | — | ||
| Q4 25 | 64.6% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 62.7% | — | ||
| Q1 25 | 67.9% | — | ||
| Q4 24 | 65.3% | — | ||
| Q3 24 | 63.2% | — | ||
| Q2 24 | 66.4% | — |
| Q1 26 | — | — | ||
| Q4 25 | 18.4% | 21.7% | ||
| Q3 25 | — | 13.2% | ||
| Q2 25 | -7.5% | 11.6% | ||
| Q1 25 | 12.2% | 14.0% | ||
| Q4 24 | 16.0% | 1.9% | ||
| Q3 24 | 13.8% | -4.7% | ||
| Q2 24 | 15.0% | 12.6% |
| Q1 26 | — | 13.8% | ||
| Q4 25 | 12.8% | 16.3% | ||
| Q3 25 | — | 9.9% | ||
| Q2 25 | -5.6% | 8.8% | ||
| Q1 25 | 7.1% | 10.5% | ||
| Q4 24 | 11.7% | 1.6% | ||
| Q3 24 | 11.6% | -4.2% | ||
| Q2 24 | 13.3% | 9.3% |
| Q1 26 | — | $1.88 | ||
| Q4 25 | $0.24 | $2.29 | ||
| Q3 25 | — | $1.38 | ||
| Q2 25 | $-0.11 | $1.21 | ||
| Q1 25 | $0.14 | $1.44 | ||
| Q4 24 | $0.22 | $0.23 | ||
| Q3 24 | $0.21 | $-0.57 | ||
| Q2 24 | $0.26 | $1.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $172.9M | $595.8M |
| Total DebtLower is stronger | $260.0M | — |
| Stockholders' EquityBook value | $2.0B | $584.7M |
| Total Assets | $2.5B | $2.8B |
| Debt / EquityLower = less leverage | 0.13× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $595.8M | ||
| Q4 25 | $172.9M | $408.9M | ||
| Q3 25 | — | $405.1M | ||
| Q2 25 | $162.2M | $367.1M | ||
| Q1 25 | $140.7M | $398.2M | ||
| Q4 24 | $177.5M | $259.4M | ||
| Q3 24 | $187.5M | $333.7M | ||
| Q2 24 | $152.9M | $283.3M |
| Q1 26 | — | — | ||
| Q4 25 | $260.0M | $100.5M | ||
| Q3 25 | — | $100.7M | ||
| Q2 25 | $346.0M | $100.9M | ||
| Q1 25 | $330.0M | $101.1M | ||
| Q4 24 | $300.0M | $101.2M | ||
| Q3 24 | $300.0M | $101.4M | ||
| Q2 24 | $319.0M | $101.6M |
| Q1 26 | — | $584.7M | ||
| Q4 25 | $2.0B | $551.0M | ||
| Q3 25 | — | $495.0M | ||
| Q2 25 | $1.9B | $457.8M | ||
| Q1 25 | $2.0B | $422.4M | ||
| Q4 24 | $2.1B | $373.3M | ||
| Q3 24 | $2.1B | $400.2M | ||
| Q2 24 | $2.1B | $393.2M |
| Q1 26 | — | $2.8B | ||
| Q4 25 | $2.5B | $2.8B | ||
| Q3 25 | — | $3.1B | ||
| Q2 25 | $2.6B | $3.3B | ||
| Q1 25 | $2.6B | $2.7B | ||
| Q4 24 | $2.7B | $2.8B | ||
| Q3 24 | $2.7B | $2.7B | ||
| Q2 24 | $2.7B | $2.7B |
| Q1 26 | — | — | ||
| Q4 25 | 0.13× | 0.18× | ||
| Q3 25 | — | 0.20× | ||
| Q2 25 | 0.18× | 0.22× | ||
| Q1 25 | 0.16× | 0.24× | ||
| Q4 24 | 0.14× | 0.27× | ||
| Q3 24 | 0.14× | 0.25× | ||
| Q2 24 | 0.15× | 0.26× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
UVE
Segment breakdown not available.
